文献速递肝病

非酒精性脂肪性肝病的医疗与社会经济成本:应对不确定性的全球框架

Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties.
PubMed 文献 · J Hepatol · 2023-02-04

本综述汇总了非酒精性脂肪性肝病(NAFLD)当前的全球医疗与社会经济成本数据,并提出优先行动。NAFLD 患者的估算医疗成本约为年龄匹配无病人群的近两倍,在晚期纤维化和终末期肝病患者中最高。NAFLD 在全球所有肝病中导致的伤残调整生命年(DALY)增幅最高。作者提出全球 NAFLD/NASH 投资框架以指导各国制定目标与战略行动。

要点

  • NAFLD 患者估算医疗成本约为年龄匹配无病人群的近两倍。
  • NAFLD 在全球所有肝病中 DALY 增幅最高。
  • 袖状胃切除术被报告为现有减重手术中对 NASH 缓解最具成本效益。

核心结论

  • 若不加以应对,NAFLD 将持续带来重大的健康、经济和社会影响,需要概念转变及跨专科、行业和政府的协同行动。

研究设计与样本

  • 综述,汇总当前全球 NAFLD 医疗与社会经济成本数据并提出优先行动。

主要发现

  • NAFLD 患者的估算医疗成本约为年龄匹配无病人群的近两倍,在晚期纤维化和终末期肝病患者中最高。
  • NAFLD 在全球所有肝病中 DALY 增幅最高。
  • NAFLD 和 NASH 特异性药物治疗尚不可用,其成本、最佳治疗时长及对肝脏相关结局和死亡率的影响存在相当大的不确定性。
  • 在现有减重手术中,袖状胃切除术被报告为对 NASH 缓解最具成本效益;胃旁路术仍非常昂贵,减重内镜数据有限。

关键数值与推荐

  • NAFLD 患者估算医疗成本约为年龄匹配无病人群的近两倍。
  • NAFLD 在全球所有肝病中 DALY 增幅最高。
  • 袖状胃切除术被报告为现有减重手术中对 NASH 缓解最具成本效益。
  • NAFLD 和 NASH 特异性药物治疗尚不可用,成本、最佳治疗时长及对肝脏相关结局和死亡率的影响存在相当大的不确定性。

临床怎么用

  • 作者提出全球 NAFLD/NASH 投资框架,以指导制定可实现且雄心勃勃的国别目标和战略行动,优化资源配置并降低 NAFLD 和 NASH 患病率。

局限性

  • NAFLD 和 NASH 特异性药物治疗尚不可用,其成本、最佳治疗时长及对肝脏相关结局和死亡率的影响存在相当大的不确定性。
  • 减重内镜数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Left unaddressed, non-alcoholic fatty liver disease (NAFLD) will continue to have substantial health, economic and social implications. To address the challenge, a paradigm shift is needed in the way NAFLD is conceptualised. Concerted, collaborative action across medical specialities, industry sectors and governments will be vital in tackling this public health threat. To drive this change, in this review, we present data on the current global healthcare and socioeconomic costs of NAFLD and highlight priority actions. The estimated healthcare costs of patients with NAFLD are nearly twice as high as their age-matched counterparts without the disease and are highest in those with advanced fibrosis and end-stage liver disease. NAFLD is accountable for the highest increase in DALYs (disability-adjusted life years) among all liver diseases globally. NAFLD and non-alcoholic steatohepatitis (NASH)-specific drug therapies are not yet available and there is considerable uncertainty regarding cost, optimal length of treatment, and their impact on liver-related outcomes and mortality. Among the currently available bariatric procedures, sleeve gastrectomy is reported to be the most cost-effective for NASH resolution. Gastric bypass remains very expensive, while data on bariatric endoscopy are limited. Lastly, we propose a global NAFLD/NASH investment framework to guide the development of achievable yet ambitious country-specific targets and strategic actions to optimise resource allocation and reduce the prevalence of NAFLD and NASH. Its focus on high-level inputs will be critical to enabling a political and financial environment that supports clinical-level implementation of NAFLD prevention, treatment and care efforts, across all settings.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Allen AM, Lazarus JV, Younossi ZM, et al. Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties. J Hepatol. 2023. PMID: 36740046. doi:10.1016/j.jhep.2023.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。